We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Development of Retinal and Brain Blood Barriers Controlled by Norrin/Frizzled4 Signaling

By LabMedica International staff writers
Posted on 27 Dec 2012
The activity of the Norrin/Frizzled4 protein pair in the embryo controls development of the retinal and brain blood barriers, and the timing of this activity is critically linked to precise blood vessel formation.

Norrin/Frizzled4 (Fz4) signaling activates the canonical Wnt pathway that controls conserved secreted signaling molecules that regulate cell-to-cell interactions during embryogenesis. More...
To determine how this signaling activity would affect the later development of the animal, investigators at Johns Hopkins University (Baltimore, MD, USA;) genetically engineered lines of mice to lack the gene for Norrin, Fz4, or for both genes. The technique that was used gave the investigators temporal and tissue-specific control of Norrin/Fz4 signaling. Other mice were engineered to express Norrin activity at an earlier stage of development than was normal.

Results published in the December 7, 2012, issue of the journal Cell revealed that early initiation of Norrin production led to premature retinal vascular invasion. Delayed Norrin production led to characteristic defects in intraretinal vascular architecture.

In the adult retina and cerebellum, gain or loss of Norrin/Fz4 signaling resulted in a cell-autonomous gain or loss, respectively, of blood retina barrier and blood-brain barrier function, indicating an ongoing requirement for Frizzled signaling in barrier maintenance and substantial plasticity in mature central nervous system vascular structure.

Although crucial to protecting the central nervous system, the blood-brain barrier also prevents drugs in the bloodstream from penetrating the brain to treat diseases. "Our research shows that blood vessel cells lacking Frizzled-4 are leaky," said senior author Dr. Jeremy Nathans, professor of molecular biology and genetics at Johns Hopkins University. "With this information in hand, we hope that someday it may be possible to temporarily loosen the blood-brain barrier, allowing life-saving drugs to pass through."

Related Links:

Johns Hopkins University



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.